obesity glp-1 news today ADA 2026 confirmed what many of us have been anticipating for years. We're entering a new era of medicine: triple agonists, oral GLP-1s, monthly injections, and therapies targeting obesity, diabetes, and GLP-1 Prescriptions Quadruple Since 2021

With concierge-style care available 24/7, our team focuses on personalized wellness support that fits your recovery goals and schedule

Increased protein intake, along with strength training, will help people lose primarily body fat during a weight loss phase

They lied to me in beginning stating my insurance was old cover with a pre authorization

Striking the balance: GLP-1/Glucagon Co-agonism as a treatment strategy for obesity

Far in the lead is Lilly with its late-stage orforglipron, which in a June 2023 Phase II readout achieved weight loss between 9.4% and 14.7% at 36 weeks

Some forecasters have predicted that the online weight-loss-drug market will grow to $150 billion in the next five years